Trial Profile

A Phase 2a, Randomized, Double-Masked, Placebo-Controlled Study Assessing the Safety and Efficacy of OK-101 Treatment in Subjects with Neuropathic Corneal Pain

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 08 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

01 May 2025 According to an OKYO Pharma media release, company announced positive data on the long-term stability of Urcosimod for the treatment of NCP in March 2025.
30 Apr 2025 According to an OKYO Pharma media release, the company plans for a meeting with FDA following evaluation of clinical data.
30 Apr 2025 According to an OKYO Pharma media release, the company plans to analyze the efficacy data from the 17 patients who have now completed the Phase 2 trial and close this single center trial now, to move forward with a multicenter trial.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com